- Research article
- Open Access
Cross-priming of cyclin B1, MUC-1 and survivin-specific CD8+T cells by dendritic cells loaded with killed allogeneic breast cancer cells
Breast Cancer Research volume 8, Article number: R65 (2006)
The ability of dendritic cells (DCs) to take up whole tumor cells and process their antigens for presentation to T cells ('cross-priming') is an important mechanism for induction of tumor specific immunity.
In vitro generated DCs were loaded with killed allogeneic breast cancer cells and offered to autologous naïve CD8+ T cells in 2-week and/or 3-week cultures. CD8+ T cell differentiation was measured by their capacity to secrete effector cytokines (interferon-γ) and kill breast cancer cells. Specificity was measured using peptides derived from defined breast cancer antigens.
We found that DCs loaded with killed breast cancer cells can prime naïve CD8+ T cells to differentiate into effector cytotoxic T lymphocytes (CTLs). Importantly, these CTLs primed by DCs loaded with killed HLA-A*0201- breast cancer cells can kill HLA-A*0201+ breast cancer cells. Among the tumor specific CTLs, we found that CTLs specific for HLA-A2 restricted peptides derived from three well known shared breast tumor antigens, namely cyclin B1, MUC-1 and survivin.
This ability of DCs loaded with killed allogeneic breast cancer cells to elicit multiantigen specific immunity supports their use as vaccines in patients with breast cancer.
Despite declining mortality rates, breast cancer ranks second among cancer related deaths in women. In the USA alone, it is estimated that more than 200,000 new cases of breast cancer will be diagnosed yearly, with that about 40,000 patients will die from breast cancer . Therefore, there is a need to develop novel therapeutic approaches to improve survival rates among patients with breast cancer.
Evidence is accumulating that naturally occurring immunity is present in patients with breast cancer against tumor associated antigens such as HER-2/neu [2, 3] and cdr2 , as well as the antigens investigated here, namely MUC-1 [5, 6], cyclin B1  and survivin . Several clinical studies have now demonstrated that immunity against tumor antigens can also be boosted or elicited in cancer patients by vaccination, most recently through the use of tumor antigen loaded dendritic cells (DCs) [9–13]. For example, in a recently reported trial , two out of ten patients with breast/ovarian cancer vaccinated with HER-2/neu or MUC-1 peptide-pulsed monocyte-derived DCs generated cytotoxic T lymphocytes (CTLs) that were able to kill HLA-A*0201 cell lines expressing these antigens. The optimal source of tumor antigens for loading of ex vivo generated DCs is yet to be determined . In particular, strategies that allow tumor antigen presentation across HLA haplotypes are needed, and several have been undergoing investigation. These include loading DCs with recombinant proteins, killed tumor cells [4, 16–18], tumor RNA [19, 20] and viral vectors that encode tumor antigens , and fusing DCs with tumor cells . In prostate cancer  and in melanoma , we previously showed that DCs loaded with killed allogeneic tumor cells cross-prime naïve CD8+ T cells to differentiate into CTLs specific for shared tumor antigens.
In breast cancer, we previously demonstrated that DCs loaded with killed breast cancer cells can induce CTLs that can kill those breast cancer cells . However, we were unable to determine the antigen specificity of these CTLs. In an extension of that work, here we demonstrate that DCs loaded with killed allogeneic breast cancer cells can prime naïve CD8+ T cells to differentiate into tumor antigen specific CTLs by confirming their specificity for three known breast cancer antigens: cyclin B1, MUC-1, and survivin.
Materials and methods
Media and reagents
Complete RPMI-1640 was supplemented with 10% heat-inactivated fetal calf serum (Hyclone, Logan, UT, USA) for DCs and 10% human serum AB (Gem cell) for T cell cultures. Cytokines used included granulocyte-macrophage colony-stimulating factor (100 ng/ml; Immunex, Amgen Thousand Oaks, CA, USA), IL-4 (25 ng/ml; R&D Systems, Minneapolis, MN, USA), soluble CD40 ligand (200 ng/ml; R&D Systems), IL-2 (10 IU/ml; R&D Systems), and IL-7 (10 IU/ml; R&D Systems). Betulinic acid (Sigma-Aldrich, St. Louis, MO, USA) was used at 10 mg/ml. Cyclin B1 peptide CB9 (sequence AKYLMELTM) was synthesized at the University of Pittsburgh Cancer Institute Peptide Synthesis facility. MUC-1 peptides D6 (sequence LLLTVLTVV) and PSA1 (sequence FLTPKKLQCV) were purchased from Bio-Synthesis (TX, Lewisville, USA). The surviving peptide library was synthesized at the Rockefeller University.
Breast cancer cell lines T47D, Hs578T, MCF-7, natural killer cell target K562 and HLA-A*0201+ T2 cells, which are targets for CTLs, were obtained from the American Type Culture Collection (Manassas, VA, USA). The Me275 melanoma cell line was a kind gift from Drs J-C Cerottini and D Rimoldi. All cell lines were maintained in complete RPMI1640 (Gibco, Invitrogen, Carlsbad, California, USA). For loading of DCs, T47D and Hs578T cells were killed by incubation with betulinic acid (Sigma-Aldrich), as described previously . MCF-7 cells were killed by gamma irradiation (80 Gy) and 24 hours of exposure to tumor necrosis factor-α (100 ng/ml; R&D Systems).
Generation of cytotoxic T lymphocytes
Naïve HLA-A*0201+ CD8+ T cells (autologous to the DCs) were depleted of other cells using anti-CD4, anti-CD14, anti-CD16, anti-CD19, anti-CD56, and anti-glycophorin A microbeads (Miltenyi, Auburn, CA, USA) and sorted based on CD8+CD45RA+CCR7+CD45RO- phenotype. DCs were generated from the adherent fraction of peripheral blood mononuclear cells by culturing for 6 days in complete RPMI1640 supplemented with granulocyte-macrophage colony-stimulating factor and IL-4, loaded with killed tumor cells, sorted, and used as stimulators of autologous purified naïve CD8+ T cells at a 1:10 ratio. Soluble CD40 ligand was added to induce DC maturation, and IL-7 (10 IU/ml in weeks 1, 2, and 3) and IL-2 (10 IU/ml in weeks 2 and 3) for T cell expansion. T cells were restimulated weekly with tumor cell loaded DCs.
51Cr cytotoxicity assay
For use as targets, T2 cells were pulsed overnight with 10 μg/ml of various peptides, labeled with 51Cr (NEN Life Science Products, Boston, Massachusetts, USA) and co-cultured with CTLs for 4 hours. Specific lysis was calculated using the following formula (where cpm is the counts/minute): % release = 100 × (cpm experiment – cpm spontaneous release)/(cpm maximum release – cpm spontaneous release). For the mAb blocking assays, anti-HLA-A, HLA-B and HLA-C antibody (W6/32; DAKO, Carpenteria, CA, USA; 5 μg/ml) or an irrelevant (control) antibody was added to the target cells 30 minutes before the addition of CTLs and left throughout the culture period.
Tumor inhibition assay
Target tumor cell lines were suspended at a concentration of 5 × 104/ml with RPMI1640 medium containing 10% AB serum and the CTLs at 106/ml. Targets cells and CTLs were co-incubated in 96-U bottom plates (Costar, Corning, Sigma-Aldrich) for 24 hours. The numbers of live and dead tumor cells were determined using trypan blue exclusion.
Intracellular cytokine staining
Primed and boosted T cells were cultured for 6 hours with DCs loaded with 15-mer peptides representing survivin peptide library. At 2 hours of stimulation, Golgi-stop™ (BD Pharmingen, San Diego, CA, USA) was added to the culture. At 6 hours of stimulation, cells were harvested and first stained with CD3-PerCP and CD8-APC mAbs, fixed and permeabilized with BD Cytofix/Cytoperm™ solution (BD), and then stained with anti-IFN-γ PE (BD Pharmingen).
T cell restimulation assay
CD8+ T cells that had undergone two stimulations with DCs loaded with killed breast cancer cells were co-incubated with autologous DCs pulsed with the survivin peptide library at a 10:1 ratio. The T cells were analyzed after an additional 5 to 7 days of culture by intracellular cytokine staining, as described above.
Nonparametric Kruskal-Wallis analysis of variance was used as indicated to assess the killing of three different target cells. P < 0.05 was considered statistically significant.
Development of breast cancer specific CD8+T cells through cross-priming
We used HLA-A*0201+ monocyte-derived DCs loaded with killed allogeneic breast cancer cells to prime in vitro autologous naïve CD45RA+CCR7+CD45RO-CD8+ T cells. The priming and weekly restimulations were performed with the addition of soluble CD40 ligand, and the T cells were maintained in the presence of 10 U/ml of cytokines IL-7 and IL-2. As shown in Figure 1, after 3 weeks of culture naïve CD8+ T cells differentiated into effector cells, as measured by expression of IFN-γ, granzymes A and B, and perforin (Figure 1a). This differentiation was observed in cultures stimulated with control DCs as well as antigen loaded DCs, but the antigen loaded DCs stimulated greater expansion of effector CD8+ T cells expressing granzymes A and B (Figure 1b to 1d). A possible explanation for the antigen-independent differentiation seen in several independent experiments using T cells from three different donors could come from the addition of T cell cytokines such as IL-7 and IL-2 to support CD8+ T cell priming.
The cytotoxic effector function of antigen-primed CD8+ T cells against breast cancer cells was analyzed in a 4-hour 51Cr release assay. As shown in Figure 2a, CD8+ T cells cultured with HLA-A*0201+ DCs loaded with killed HLA-A*0201+ MCF7 breast cancer cells were able to kill MCF7 cells but not natural killer sensitive K562 cells. Such effective priming of tumor specific CD8+ T was achieved with naïve T cells from three different donors. Tumor cell lysis could be abolished by pretreatment of the target MCF7 cells with anti-MHC class I antibody, thus confirming that induction of HLA class I restricted CTLs was taking place in these cultures (Figure 2b).
To confirm that cross-priming had occurred, naïve HLA-A*0201+ CD8+ T cells were exposed to three stimulations with autologous HLA-A*0201+ DCs loaded with HLA-A*0201- breast cancer cell lines T47D or Hs578T and tested on HLA-A*0201+ MCF-7 target cells in a 4-hour 51Cr release assay (Figure 3a and 3b) and a 24-hour tumor inhibition assay  (Figure 3c). As shown in Figure 3, CTLs primed in these cultures could kill HLA-A*0201+ MCF7 breast cancer cells not used in the priming, thus demonstrating cross-priming against antigens shared between the priming and the target breast cancer cell lines (Figure 3a and 3b). These antigens were mostly breast cancer specific, as further demonstrated by the inability of the breast cancer primed CTLs to kill HLA-A*0201+ Me275 melanoma cells (Figure 3a and 3b). These results were obtained with CD8+ T cells isolated from four different healthy donors in four independent experiments. These data clearly show that DCs loaded with killed allogeneic breast cancer cells can cross-prime naïve CD8+ T cells to differentiate into CTLs specific for antigens shared between breast cancer cell lines.
Specificity of breast cancer cross-primed cytotoxic T lymphocytes for defined shared tumor antigens
The desired objective of loading DCs with killed breast cancer cells was to prime a polyclonal population of antigen specific CTLs. To determine whether this was indeed the case, we tested the primed CTL cultures for the presence of T cells specific for three well known tumor antigens expressed in breast cancers, namely cyclin B1, MUC-1 and survivin.
Cyclin B1-specific cytotoxic T lymphocytes
The discovery of cyclin B1 as a potential target for T cells in patients with breast as well as head and neck cancers expanded the spectrum of defined tumor antigens expressed in breast cancer . Among the breast cancer cells we used, T47D cells demonstrated the greatest over-expression and cytoplasmic accumulation of cyclin B1 (Figure 4a). Thus, CD8+ T cells that were primed with DCs loaded with killed T47D cells were assayed for their capacity to kill cyclin B1 peptide pulsed T2 target cells. As shown in Figure 4b, T2 cells pulsed with the cyclin B1 peptide were killed efficiently whereas the control targets, namely T2 cells pulsed with irrelevant peptide or natural killer cell sensitive K562 cells, were killed at a significantly lower (background) level. These results were obtained with naïve CD8+ T cells from three different healthy donors and demonstrate successful cross-priming of antigen specific CTLs by DCs loaded with killed tumor cells.
MUC-1 specific cytotoxic T lymphocytes
T47D cells are also positive for the tumor antigen MUC-1, so we anticipated that the above cultures primed with T47D-loaded DCs would also yield T cells specific for MUC-1. This turned out not to be the case Figure 5a shows that MUC-1 peptide pulsed T2 cells were not killed. Earlier studies by some of us [25–27] demonstrated that MUC-1 glycoprotein, which is over-expressed and secreted by breast cancer cells, is endocytosed by DCs but is mostly retained in early endosomes; this leads to its inefficient processing and presentation to T cells, and hence a lower frequency of MUC-1 specific effector cells. We assumed that this was responsible for the low (undetectable) frequency of cross-primed effector CTLs, and in order to increase further the MUC-1 specific CTL frequency we gave the cultures one additional restimulation with DCs pulsed with a defined MUC-1 derived peptide. Thus, naïve CD8+ T cells were primed for 3 weeks with DCs loaded with killed T47D breast cancer cells, and at day 7, after the third stimulation, the T cells were restimulated for 5 days with MUC-1 peptide pulsed autologous DCs. As shown in Figure 5b, T cells given one additional restimulation with peptide-pulsed DCs were capable of significant lysis of MUC-1 peptide pulsed but not control T2 cells pulsed with irrelevant peptide. Control CD8+ T cells from 3-week cultures primed with control (not loaded) DCs and restimulated with peptide pulsed DCs were unable to expand MUC-1 specific T cells in this assay (<1% specific lysis at an effector:target ratio of 30:1). Thus, DCs loaded with killed allogeneic breast cancer cells can also prime (albeit at lower frequency) naïve CD8+ T cells to differentiate into MUC-1 peptide specific CTLs.
Survivin-specific T cells
To evaluate further the repertoire breadth of elicited CD8+ T cell immunity, we assessed the priming of CD8+ T cells against the shared tumor antigen survivin [28–30]. Here, we used another approach to analyze specificity and effector function (overlapping peptide libraries and intracytoplasmic IFN-γ staining), with the intention being to demonstrate priming to many different peptides derived from the same tumor antigen. Survivin positive HLA-A*0201+ MCF7 killed breast cancer cells were used to load DCs. The T cells were assessed using a recall memory strategy as was used for the MUC-1 specific responses described above. Our expectation was that T cells specific for each individual peptide might be present in low frequency. Thus, after priming and boosting with DCs loaded with killed MCF7 breast cancer cells, the third T cell stimulation was carried out with DCs loaded with the library of overlapping 15-mer peptides representing the full length of survivin. Thereafter, the T cells were briefly (6 hours) restimulated with DCs loaded with survivin derived 15-mer peptides, stained with anti-IFN-γ mAbs and analyzed by flow cytometry (Figure 6). As shown in Figure 6, IFN-γ secretion was detected in T cells exposed to peptides 25 and 26. IFN-γ secreting T cells are predominantly those that label with anti-CD8 mAbs. Further analysis demonstrated that peptide 26 contained a 10 amino acid sequence consistent with the previously reported HLA-A*0201 restricted survivin peptide ELTLGEFLKL , and that peptide 25 contained an eight amino acid sequence (ELTLGEFL) from this peptide.
Using different target antigens and different assays to measure CTL function, we demonstrated that DCs loaded with killed allogeneic breast cancer cells cross-prime naïve CD8+ T cells to differentiate into breast cancer specific effector CTLs. The elicited CTLs demonstrate specific effector function, as measured by their capacity to kill breast cancer cells used for priming, to kill T2 cells pulsed with defined peptides derived from breast cancer antigens, and to secrete IFN-γ upon peptide exposure. Among the primed CTLs, we demonstrate at least three specificities against the known shared breast tumor antigens cyclin B1, MUC-1, and survivin.
Interestingly, we observed differences in the priming of CD8+ T cells with distinct specificities that were consistent with the unique nature of each antigen. Thus, T cells specific for cyclin B1 could be detected after priming and two rounds of boosting with DCs loaded with killed breast cancer cells. However, this strategy did not permit detection of MUC-1 specific T cells, which required an additional boost with MUC-1 peptide pulsed DCs. We ascribe this to the differences in efficiency of presentation of different antigens by loaded DCs and/or differences in the frequency of precursor T cells with these specificities. Indeed, cyclin B1 represents a protein antigen whose function as a tumor antigen is associated with increased cytoplasmic accumulation followed by degradation through ubiquitination . This might make it more accessible to the DC antigen processing/presentation machinery than the transmembrane MUC-1 glycoprotein. Previous studies by some of us [25–27] demonstrated that MUC-1 and HER-2/neu are retained in DC early endosomes, leading to inefficient processing and cross-presentation to T cells. These observations, together with our earlier study and the lack of specificity to some other defined breast cancer antigens, including HER-2/neu , suggest that efficient cross-presentation of individual tumor antigens by DCs loaded with killed breast cancer cells will depend on the nature of these antigens or the form in which they are taken up by DCs. For example, although we found that DCs loaded with whole tumor cells are not efficient in cross-presenting MUC-1, a recent study  demonstrated that loading DCs with breast cancer cell lysates permits more efficient priming of MUC-1 specific CD8+ T cells. It is difficult to determine whether the difference in the outcomes between that study and ours is due to a real difference between loading DCs with whole tumor cells and loading them with tumor cell lysate, or to a difference in how the MUC-1 specific T cells were detected. CD8+ T cells in that report were measured based on tetramer binding but in our study measurement was based on a functional assay, specifically the activity of CTLs against target cells expressing MUC-1 peptide.
Thus, our data offer experimental proof that using DCs loaded with killed allogeneic breast cancer cells for antigen presentation leads to priming of T cells to multiple tumor antigens, some that are already known and could be tested here, and potentially many more unknown but nevertheless important shared tumor antigens. The advantage of this approach is the ability to generate, with one vaccine, T cells specific for many tumor antigens and in many patients, regardless of HLA type. Although it is conceivable that part of the generated response might be due to HLA mismatch, breast cancer tumor antigen specific immune responses were also generated. Finally, we previously demonstrated the validity of this approach in patients with stage IV melanoma . In that study patients were vaccinated with DCs loaded with killed allogeneic melanoma cells. We that melanoma specific immune responses were induced and, perhaps more importantly, durable (>33 months) objective clinical responses were identified in 10% of patients in whom conventional therapy failed. Thus, this vaccination strategy might now be tested in phase I studies in patients with metastatic breast cancer.
This ability of DCs loaded with killed allogeneic breast cancer cells to elicit multiantigen specific immunity supports their use as vaccines in patients with breast cancer.
cytotoxic T lymphocyte
Ries L, Eisner M, Kosary C: SEER Cancer Statistics Review, 1975–2000. 2003, Bethesda, MD: National Cancer Institute
Disis ML, Bernhard H, Gralow JR, Hand SL, Emery SR, Calenoff E, Cheever MA: Immunity to the HER-2/neu oncogenic protein. Ciba Found Symp. 1994, 187: 198-207.
Disis ML, Cheever MA: HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv Cancer Res. 1997, 71: 343-371.
Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB: Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med. 1998, 4: 1321-1324. 10.1038/3315.
Nagorsen D, Scheibenbogen C, Schaller G, Leigh B, Schmittel A, Letsch A, Thiel E, Keilholz U: Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients. Int J Cancer. 2003, 105: 221-225. 10.1002/ijc.11052.
Feuerer M, Beckhove P, Bai L, Solomayer EF, Bastert G, Diel IJ, Pedain C, Oberniedermayr M, Schirrmacher V, Umansky V: Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med. 2001, 7: 452-458. 10.1038/86523.
Kao H, Marto JA, Hoffmann TK, Shabanowitz J, Finkelstein SD, Whiteside TL, Hunt DF, Finn OJ: Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med. 2001, 194: 1313-1323. 10.1084/jem.194.9.1313.
Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, thor Straten P: Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 2001, 61: 5964-5968.
Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen- pulsed dendritic cells. Nat Med. 1996, 2: 52-58. 10.1038/nm0196-52.
Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998, 4: 328-332. 10.1038/nm0398-328.
Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, et al: Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 1999, 190: 1669-1678. 10.1084/jem.190.11.1669.
Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, et al: Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 2002, 99: 1517-1526. 10.1182/blood.V99.5.1517.
Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, et al: Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res. 2001, 61: 6451-6458.
Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W: Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood. 2000, 96: 3102-3108.
Banchereau J, Palucka AK: Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005, 5: 296-306. 10.1038/nri1592.
Albert ML, Sauter B, Bhardwaj N: Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 1998, 392: 86-89. 10.1038/32183.
Nouri-Shirazi M, Banchereau J, Bell D, Burkeholder S, Kraus ET, Davoust J, Palucka KA: Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol. 2000, 165: 3797-3803.
Berard F, Blanco P, Davoust J, Neidhart-Berard EM, Nouri-Shirazi M, Taquet N, Rimoldi D, Cerottini JC, Banchereau J, Palucka AK: Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med. 2000, 192: 1535-1544. 10.1084/jem.192.11.1535.
Boczkowski D, Nair SK, Snyder D, Gilboa E: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med. 1996, 184: 465-472. 10.1084/jem.184.2.465.
Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E: Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med. 1997, 186: 1177-1182. 10.1084/jem.186.7.1177.
Ribas A, Butterfield LH, Glaspy JA, Economou JS: Cancer immunotherapy using gene-modified dendritic cells. Curr Gene Ther. 2002, 2: 57-78. 10.2174/1566523023348129.
Phan V, Errington F, Cheong SC, Kottke T, Gough M, Altmann S, Brandenburger A, Emery S, Strome S, Bateman A, et al: A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines. Nat Med. 2003, 9: 1215-1219. 10.1038/nm923.
Neidhardt-Berard EM, Berard F, Banchereau J, Palucka AK: Dendritic cells loaded with killed breast cancer cells induce differentiation of tumor-specific cytotoxic T lymphocytes. Breast Cancer Res. 2004, 6: R322-R328. 10.1186/bcr794.
Paczesny S, Shi H, Saito H, Mannoni P, Fay J, Banchereau J, Palucka AK: Measuring melanoma-specific cytotoxic T lymphocytes elicited by dendritic cell vaccines with a tumor inhibition assay in vitro. J Immunother. 2005, 28: 148-157. 10.1097/01.cji.0000154247.97254.ef.
Finn OJ, Jerome KR, Henderson RA, Pecher G, Domenech N, Magarian-Blander J, Barratt-Boyes SM: MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev. 1995, 145: 61-89. 10.1111/j.1600-065X.1995.tb00077.x.
Hiltbold EM, Vlad AM, Ciborowski P, Watkins SC, Finn OJ: The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J Immunol. 2000, 165: 3730-3741.
Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ: MUC1 immunobiology: from discovery to clinical applications. Adv Immunol. 2004, 82: 249-293.
Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998, 58: 5315-5320.
Schmitz M, Diestelkoetter P, Weigle B, Schmachtenberg F, Stevanovic S, Ockert D, Rammensee HG, Rieber EP: Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res. 2000, 60: 4845-4849.
Idenoue S, Hirohashi Y, Torigoe T, Sato Y, Tamura Y, Hariu H, Yamamoto M, Kurotaki T, Tsuruma T, Asanuma H, et al: A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin Cancer Res. 2005, 11: 1474-1482. 10.1158/1078-0432.CCR-03-0817.
Bohnenkamp HR, Coleman J, Burchell JM, Taylor-Papadimitriou J, Noll T: Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1-specific CD8+ T cells identified by peptide-MHC-class-I-tetramers. Cell Immunol. 2005, 231: 112-125. 10.1016/j.cellimm.2004.12.007.
Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J, Banchereau J: Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother. 2006, 29: 545-557. 10.1097/01.cji.0000211309.90621.8b.
We thank Dr Joseph Fay, Bi-Jue Chang, Nathalie Piqueras, Doris Wood, and Susan Hicks for help with recruitment and follow up of healthy volunteers. We thank Lynnette Walters at BIIR Cell and Tissue Procurement Core; Susan Burkeholder, Jennifer Finholt-Perry and Fabienne Kerneis at BIIR GMP Lab; and Elizabeth T Kraus and Sebastien Coquery at BIIR Flow Cytometry Core for technical help; and Cindy Samuelsen and Nicolas Taquet for invaluable help. We thank Dr Michael Ramsay for continuous support.
Supported by NIH grants CA89440 (AKP), PO-1 CA84512 (AKP and JB), CA78846 (JB), CA56103 (OJF) and CA090440 (OJF); and FWFAustria (Schroedinger Stipendium, J2255-B08: PD). JB holds Caruth Chair for Transplant Immunology Research. AKP holds Ramsay Chair for Cancer Immunology Research.
Dr. Jacques Banchereau has been a consultant for Argos Therapeutics and is a scientific founder of ODC Therapy, Inc., two private companies, and has stock-options for both. Dr. Anna Karolina Palucka is a scientific founder of ODC Therapy, Inc., a private company, and has stock-options. These private companies are related to dendritic cell vaccines. Neither one of them has in any way supported the study, the results of which are described in the current manuscript.
HS designed and performed the experiments, analyzed the data, and wrote the manuscript. PD designed and performed experiments, and analyzed the data. CD performed experiments and analyzed the data. OJF designed experiments, analyzed the data, and wrote the manuscript. JB designed experiments, analyzed the data, and wrote the manuscript. AKP led the study, designed the experiments, analyzed the data, and wrote the manuscript.
Authors’ original submitted files for images
About this article
Cite this article
Saito, H., Dubsky, P., Dantin, C. et al. Cross-priming of cyclin B1, MUC-1 and survivin-specific CD8+T cells by dendritic cells loaded with killed allogeneic breast cancer cells. Breast Cancer Res 8, R65 (2006). https://0-doi-org.brum.beds.ac.uk/10.1186/bcr1621
- Breast Cancer Cell
- Tumor Antigen
- T47D Cell
- Betulinic Acid
- Soluble CD40 Ligand